China's ChiNext fell 2.00 pct, the Shenzhen Component dropped 1.01 pct and the Shanghai Composite rose 0.02 pct; optical-chip and electronic-component sectors led declines.

Phrontline Biopharma, a China-based antibody‑drug conjugate (ADC) developer, said it closed a Series A round of nearly $40m, bringing total new investment to about $100m over the past year. The round was led by Yuanhe Origin and Decheng Capital, with participation from Longpan Investment, Jifeng Capital, Mifang Health Fund, Songqing Capital and Jianfa Emerging Investment; Dianshi Capital served as exclusive financial adviser. Proceeds will accelerate clinical development of the core pipeline, support IND filings for differentiated reserve candidates, build a new payload platform and expand international collaborations and capitalization efforts.

美国至11月6日当周EIA取暖油库存 33.5万桶，前值-20.3万桶。